WallStSmart
GLYC

GlycoMimetics Inc

NASDAQ: GLYC · HEALTHCARE · BIOTECHNOLOGY

$0.16
+0.00% today

Updated 2026-04-30

Market cap
$10.13M
P/E ratio
P/S ratio
1,095.16x
EPS (TTM)
$-46.00
Dividend yield
52W range
$0 – $18
Volume

GlycoMimetics Inc (GLYC) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
-13.6%
Last 4 quarters
Revenue YoY growth
Most recent quarter
EPS YoY growth
+100.0%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-06-30$0.00$0.00
2025-03-31$-0.05$-0.04+20.0%
2024-12-31$-0.09$-0.11-24.4%$54086.00+440.9%
2024-09-30$-0.11$-0.15-36.4%
2024-06-30$-0.17$-0.16+5.9%
2024-03-31$-0.16$-0.17-6.3%
2023-12-31$-0.15$-0.14+6.7%$10000.00+13233.3%
2023-09-30$-0.14$-0.14+0.0%
2023-06-30$-0.18$-0.13+27.8%
2023-03-31$-0.17$-0.17+0.0%
2022-12-31$-0.17$-0.19-11.8%$75.00
2022-09-30$-0.26$-0.16+38.5%

Frequently asked questions

Has GlycoMimetics Inc beaten earnings estimates?
GlycoMimetics Inc has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of -13.6% over the last 3 quarters.